Skip to main content

Advertisement

SpringerLink
Log in

Statin myopathy

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Many different classes of medications can cause toxic myopathy. One of the most frequently implicated classes is the statins. Statin myotoxicity ranges from asymptomatic creatine kinase elevations or myalgias to muscle necrosis and fatal rhabdomyolysis. Statins may also cause an autoimmune myopathy requiring immunosuppressive treatment. The mechanisms of statin myotoxicity are unclear. If unrecognized in its early manifestations, complications from continued statin therapy may lead to rhabdomyolysis and death. Risk factors for myotoxicity include concomitant medication use and medical conditions, and the patient’s underlying genetic constitution. We review these considerations along with the recommended evaluation and treatment for patients presenting with statin myotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003, 289:1681–1690.

    Article  PubMed  CAS  Google Scholar 

  2. Baer AN, Wortmann RL: Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 2007, 19:67–73.

    Article  PubMed  CAS  Google Scholar 

  3. Franc S, Dejager S, Bruckert E, et al.: A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 2003, 17:459–465.

    Article  PubMed  CAS  Google Scholar 

  4. Weffald LA, Flach LA: Myopathy associated with atorvastatin-ezetimibe combination therapy. Pharmacotherapy 2007, 27:309–311.

    Article  PubMed  CAS  Google Scholar 

  5. Meas T, Cimadevilla C, Timsit J, et al.: Elevation of CKP induced by ezetimibe in monotherapy: report on two cases. Diabetes Metab 2006, 32:364–366.

    Article  PubMed  CAS  Google Scholar 

  6. Simard C, Poirier P: Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol 2006, 22:141–144.

    PubMed  Google Scholar 

  7. Davidson MH, Maccubbin D, Stepanavage M, et al.: Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006, 97:223–228.

    Article  PubMed  CAS  Google Scholar 

  8. Schindler C, Thorns M, Matschke K, et al.: Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin. Clin Ther 2007, 29:172–176.

    Article  PubMed  CAS  Google Scholar 

  9. Baker SK, Tarnopolsky MA: Statin-associated neuromyotoxicity. Drugs Today (Barc) 2005, 41:267–293.

    Article  CAS  Google Scholar 

  10. Liao JK: Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002, 110:285–288.

    Article  PubMed  CAS  Google Scholar 

  11. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89–118.

    Article  PubMed  CAS  Google Scholar 

  12. Liao JK: Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005, 16:624–629.

    Article  PubMed  CAS  Google Scholar 

  13. Rundek T, Naini A, Sacco R, et al.: Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004, 61:889–892.

    Article  PubMed  Google Scholar 

  14. Tokinaga K, Oeda T, Suzuki Y, Matsushima Y: HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism. Endocr J 2006, 53:401–405.

    Article  PubMed  CAS  Google Scholar 

  15. Vladutiu GD, Simmons Z, Isackson PJ, et al.: Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006, 34:153–162.

    Article  PubMed  CAS  Google Scholar 

  16. Jose J, Saravu K, Shastry BA: Atorvastatin-induced earlyonset rhabdomyolysis in a patient with nephrotic syndrome. Am J Health Syst Pharm 2007, 64:726–729.

    Article  PubMed  CAS  Google Scholar 

  17. Mahboobi SK, Shohat EZ, Jellinek SP, Rose M: Systemic infections can decrease the threshold of statin-induced muscle injury. South Med J 2006, 99:403–404.

    Article  PubMed  Google Scholar 

  18. Oh J, Ban MR, Miskie BA, et al.: Genetic determinants of statin intolerance. Lipids Health Dis 2007, 6:7.

    Article  PubMed  CAS  Google Scholar 

  19. Zuccaro P, Mombelli G, Calabresi L, et al.: Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res 2007, 55:310–317.

    Article  PubMed  CAS  Google Scholar 

  20. Schmitz G, Langmann T: Pharmacogenomics of cholesterollowering therapy. Vasc Pharmacol 2006, 44:75–89.

    Article  CAS  Google Scholar 

  21. Shitara Y, Sugiyama Y: Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112:71–105.

    Article  PubMed  CAS  Google Scholar 

  22. Bottorff MB: Statin safety and drug interactions: clinical implications. Am J Cardiol 2006, 97:27C–31C.

    Article  PubMed  CAS  Google Scholar 

  23. Schmidt GA, Hoehns JD, Purcell JL, et al.: Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med 2007, 20:411–416.

    Article  PubMed  Google Scholar 

  24. Christopher-Stine L: Statin myopathy: an update. Curr Opin Rheumatol 2006, 18:647–653.

    Article  PubMed  CAS  Google Scholar 

  25. Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006, 291:C1208–C1212.

    Article  PubMed  CAS  Google Scholar 

  26. Vasconcelos OM, Campbell WW: Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2006, 30:803–807.

    Article  Google Scholar 

  27. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH: Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005, 165:2671–2676.

    Article  PubMed  Google Scholar 

  28. Kashani A, Phillips CO, Foody JM, et al.: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788–2797.

    Article  PubMed  CAS  Google Scholar 

  29. Phillips PS, Haas RH, Bannykh S, et al.: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581–585.

    PubMed  Google Scholar 

  30. Soininen K, Niemi M, Kilkki E, et al.: Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol 2006, 98:51–54.

    Article  PubMed  CAS  Google Scholar 

  31. Thompson PD, Zmuda JM, Domalik LJ, et al.: Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997, 46:1206–1210.

    Article  PubMed  CAS  Google Scholar 

  32. Dobkin BH: Statin-related myopathy. Arch Intern Med 2006, 166:1232.

    Article  PubMed  Google Scholar 

  33. Staffa JA, Chang J, Green L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002, 346:539–540.

    Article  PubMed  Google Scholar 

  34. Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 2006, 97:S52–S60.

    Article  CAS  Google Scholar 

  35. Antons KA, Williams CD, Baker SK, Phillips PS: Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006, 119:400–409.

    Article  PubMed  CAS  Google Scholar 

  36. Clark DW, Strandell J: Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol 2006, 62:473–479.

    Article  PubMed  CAS  Google Scholar 

  37. Noel B, Panizzon RG: Lupus-like syndrome associated with statin therapy. Dermatology 2004, 208:276–277.

    Article  PubMed  Google Scholar 

  38. Fauchais AL, Iba BJ, Maurage P, et al.: Polymyositis induced or associated with lipid-lowering drugs: five cases [French]. Rev Med Interne 2004, 25:294–298.

    Article  PubMed  Google Scholar 

  39. Needham M, Fabian V, Knezevic W, et al.: Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromusc Disord 2007, 17:194–200.

    Article  PubMed  Google Scholar 

  40. D’Alessandro AM, Mulford GJ: An unusual case of electromyographic recorded myokymic potentials: a case report. Arch Phys Med Rehab 2002, 83:727–729.

    Article  Google Scholar 

  41. Gaist D, Jeppesen U, Andersen M, et al.: Statins and risk of polyneuropathy: a case-control study. N Engl J Med 2002, 58:1333–1337.

    CAS  Google Scholar 

  42. Campbell WW: Statin myopathy: the iceberg or its tip? Muscle Nerve 2006, 34:387–390.

    Article  PubMed  CAS  Google Scholar 

  43. Seehusen DA, Asplund CA, Johnson DR, Horde KA: Primary evaluation and management of statin therapy complications. South Med J 2006, 99:250–256.

    Article  PubMed  Google Scholar 

  44. Pasternak RC, Smith SC, Bairey-Merz CN, et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002, 33:2337–2341.

    Article  PubMed  Google Scholar 

  45. Marcoff L, Thompson PD: The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007, 49:2231–2237.

    Article  PubMed  CAS  Google Scholar 

  46. Caso G, Kelly P, McNurlan MA, Lawson WE: Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409–1412.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Martin Army Community Hospital, 7950 Martin Loop, Fort Benning, GA, 31905-5637, USA

    Kristofer A. Radcliffe

Authors
  1. Kristofer A. Radcliffe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William W. Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristofer A. Radcliffe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Radcliffe, K.A., Campbell, W.W. Statin myopathy. Curr Neurol Neurosci Rep 8, 66–72 (2008). https://doi.org/10.1007/s11910-008-0011-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-008-0011-4

Keywords

Search

Navigation